|
Aug 29
|
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
|
|
Aug 27
|
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates
|
|
Jul 29
|
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
|
|
Jun 14
|
Affimed N.V. (NASDAQ:AFMD) Upgraded by Laidlaw
|
|
Jun 12
|
Affimed Reports First Quarter 2024 Financial Results & Business Update
|
|
Jun 7
|
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
|
|
May 29
|
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
|
|
May 28
|
Affimed Announces Annual General Meeting of Shareholders
|
|
May 23
|
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
|
|
May 14
|
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
|
|
May 14
|
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
|
|
Apr 24
|
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
|
|
Apr 24
|
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
|
|
Apr 17
|
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
|
|
Apr 4
|
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
|
|
Apr 1
|
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Affimed Reports 2023 Financial Results and Operational Progress
|
|
Mar 21
|
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
|
|
Mar 14
|
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know
|
|
Mar 6
|
Affimed Announces 1-for-10 Reverse Stock Split
|